EndoV inhibitors are a class of small molecules that target and inhibit the enzyme Endonuclease V (EndoV), which plays a crucial role in DNA repair processes. These inhibitors are primarily designed for research purposes and have garnered significant attention in the field of molecular biology and genomics due to their ability to modulate DNA repair mechanisms. EndoV is an endonuclease enzyme found in various organisms, including bacteria and certain archaea. Its primary function is to participate in the base excision repair (BER) pathway, which is responsible for repairing damaged DNA bases. In the context of this repair mechanism, EndoV specifically recognizes and cleaves DNA at sites where deaminated adenine (hypoxanthine) is present in the DNA strand. This cleavage is a critical step in the removal of damaged DNA bases to facilitate the subsequent repair of the DNA strand.
EndoV inhibitors are synthesized to interfere with the enzymatic activity of EndoV, preventing it from recognizing and cleaving the deaminated adenine sites in DNA. These inhibitors are valuable tools in molecular biology research, as they allow scientists to study the effects of impairing the BER pathway and disrupting specific DNA repair processes. Understanding the role of EndoV and its inhibition can provide insights into the broader context of DNA repair mechanisms, mutagenesis, and genome stability. Researchers use EndoV inhibitors to investigate the consequences of EndoV dysfunction in cells and organisms, shedding light on the intricate molecular pathways that maintain DNA integrity. Additionally, these inhibitors can be employed in studies aimed at elucidating the biochemical and structural aspects of EndoV and its interactions with DNA, contributing to a deeper understanding of DNA repair mechanisms at the molecular level.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Inhibits FBL13 by modulating protein ubiquitination. | ||||||
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $50.00 $374.00 $2071.00 | 18 | |
Targets FBL13, altering its substrate binding activity. | ||||||
Pomalidomide | 19171-19-8 | sc-364593 sc-364593A sc-364593B sc-364593C sc-364593D sc-364593E | 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $100.00 $143.00 $312.00 $468.00 $1248.00 $1997.00 | 1 | |
Modulates FBL13-mediated protein degradation pathways. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
Blocks FBL13 activity by inhibiting proteasome function. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
Suppresses FBL13 by inhibiting the NEDDylation process. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Inhibits FBL13 through proteasome inhibition. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $62.00 $225.00 $779.00 | 24 | |
Disrupts the FBL13-p53 interaction, stabilizing p53. | ||||||
(–)-Nutlin-3 | 675576-98-4 | sc-222086 sc-222086A | 1 mg 5 mg | $122.00 $219.00 | 2 | |
Similar to Nutlin-3, it targets FBL13-p53 interaction. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Regulates FBL13-related protein degradation. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
Blocks FBL13 via proteasome inhibition. | ||||||